• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Bevacizumab"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-19 of 19

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Cancer of unknown primary site: 20 questions to be answered 

      Pavlidis, Nicholas; Pentheroudakis, George (2010)
      Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...

    • Article  

      Cancer of unknown primary: What kind of chemotherapy? what kind of disease? 

      Pentheroudakis, George; Pavlidis, Nicholas (2009)

    • Article  

      Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 

      Pentheroudakis, George; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas (2010)

    • Article  

      Carcinoma of unknown primary (CUP) 

      Pavlidis, Nicholas; Fizazi, K. (2009)
      Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...

    • Article  

      The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010 

      Cutsem, E. van; Dicato, M.; Geva, R.; Arber, N.; Bang, Y.; Benson, A.; Cervantes, A.; Diaz-Rubio, E.; Ducreux, M.; Glynne-Jones, R.; Grothey, Axel; Haller, D.; Haustermans, K.; Kerr, D.; Nordlinger, B.; Marshall, J.; Minsky, B. D.; Kang, Y. K.; Labianca, R.; Lordick, F.; Ohtsu, A.; Pavlidis, Nicholas; Roth, A.; Rougier, P.; Schmoll, H. J.; Sobrero, A.; Tabernero, Josep; Velde, C. van de; Zalcberg, J. (2011)
      Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics ...

    • Article  

      Forty years experience of treating cancer of unknown primary 

      Pavlidis, Nicholas (2007)
      Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists ...

    • Article  

      Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review 

      Boussios, Stergios; Seraj, E.; Zarkavelis, George; Petrakis, Dimitrios; Kollas, Aristomenes; Kafantari, Aikaterini; Assi, A.; Tatsi, K.; Pavlidis, Nicholas; Pentheroudakis, George (2016)
      Background Cervical cancer is the fourth most common cancer affecting women worldwide. Despite advances in screening and human papillomavirus (HPV) vaccination, a significant number of women present with or develop advanced ...

    • Article  

      Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review 

      Pentheroudakis, George; Greco, F. A.; Pavlidis, Nicholas (2009)
      Background: Gene expression profiling platforms were recently shown to accurately assign cancer of unknown primary (CUP) to a primary tissue of origin, with unknown impact on patient outcome. We examined chemotherapy ...

    • Article  

      Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer 

      Mauri, D.; Polyzos, N. P.; Salanti, G.; Pavlidis, Nicholas; Ioannidis, J. P. A. (2008)
      Background: Many systemic nonhormonal regimens have been evaluated across several hundreds of randomized trials in advanced breast cancer. We aimed to quantify the relative merits of these regimens in prolonging survival. ...

    • Article  

      Neuroendocrine carcinoma of unknown primary: A systematic review of the literature and a comparative study with other neuroendocrine tumors 

      Stoyianni, A.; Pentheroudakis, George; Pavlidis, Nicholas (2011)
      Introduction: Neuroendocrine carcinomas of unknown primary (NCUP) represent a specific subset with relatively favorable prognosis. Data on biology, management and outcome of NCUP patients have not been systematically ...

    • Article  

      Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets 

      Pavlidis, Nicholas (2012)
      Cancer of unknown primary sites (CUP) is a compilation of various malignant entities-the majority of which behave aggressively and carry poor prognosis. CUP is classified into two different clinicopathological groups: the ...

    • Article  

      Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection 

      Constantinidou, Anastasia; Cunningham, David; Shurmahi, F.; Asghar, Uzma; Barbachano, Yolanda; Khan, Aamir; Mudan, Satvinder; Rao, Sudha Ramachandra; Chau, Ian (2013)
      Background: Patients with colorectal cancer (CRC) and liver metastases benefit from perioperative chemotherapy and liver resection. The potential benefit of adding bevacizumab is yet to be defined. The impact of bevacizumab ...

    • Article  

      Perspectives for targeted therapies in cancer of unknown primary site 

      Pentheroudakis, George; Pavlidis, Nicholas (2006)
      Cancer of unknown primary site (CUP) ranks as the fourth most common cause of cancer deaths. Regression of the primary, early development of systemic metastases and resistance to therapy are hallmarks of this heterogeneous ...

    • Article  

      Probing the unknown in cancer of unknown primary: Which way is the right way? 

      Pentheroudakis, George; Pavlidis, Nicholas (2010)

    • Article  

      A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: A translational research study of the Hellenic Cooperative Oncology Group (HeCOG) 

      Pentheroudakis, George; Kotoula, V.; Fountzilas, E.; Kouvatseas, G.; Basdanis, G.; Xanthakis, I.; Makatsoris, T.; Charalambous, E.; Papamichael, D.; Samantas, E.; Papakostas, P.; Bafaloukos, Dimitrios; Razi, E. D.; Christodoulou, C.; Varthalitis, I.; Pavlidis, Nicholas; Fountzilas, George (2014)
      Background: Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor ...

    • Article  

      Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis 

      Golfinopoulos, Vassilis; Salanti, G.; Pavlidis, Nicholas; Ioannidis, J. P. A. (2007)
      Background: Many randomised trials have compared different systemic treatment regimens in patients with advanced colorectal cancer. While survival advances have apparently been achieved, the magnitude of these incremental ...

    • Article  

      Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management 

      Boussios, Stergios; Pentheroudakis, George; Katsanos, K.; Pavlidis, Nicholas (2012)
      The toxicity of cancer chemotherapy is among the most important factors limiting its use. Clear delineation and communication of benefits and risks is an essential component of treatment decisions. Gastrointestinal toxicity ...

    • Article  

      Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors 

      Greco, F. A.; Pavlidis, Nicholas (2009)
      The treatment for patients with unknown primary carcinoma, particularly those with unfavorable prognosis factors, has changed in the last decade, and continues to evolve. Empiric chemotherapy trials reported since 2000 ...

    • Article  

      Treatment of colorectal cancer in the elderly: A review of the literature 

      Golfinopoulos, Vassilis; Pentheroudakis, George; Pavlidis, Nicholas (2006)
      Although major progress has been achieved in the treatment of colorectal cancer, there are still several questions open for discussion concerning the management of elderly colorectal cancer patients. We conducted a review ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD